Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference
08 août 2023 10h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification...
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
17 mai 2023 07h00 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, May 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, disclosed today...
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
16 mai 2023 07h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces...
Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
11 avr. 2023 08h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company focused on the...
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
31 mars 2023 09h45 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company that creates blood...
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
15 nov. 2022 07h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy
13 oct. 2022 08h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”
06 oct. 2022 08h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
04 oct. 2022 09h00 HE
|
Sigyn Therapeutics, Inc.
- Independent Directors Bring Expertise in Intellectual Property, Finance, Healthcare Delivery, and More - SAN DIEGO, CA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics,...
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
14 sept. 2022 09h00 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address...